LOUISIANA COMMUNITY AIDS RESEARCH PROGRAM (CPCRA)
路易斯安那社区艾滋病研究计划 (CPRA)
基本信息
- 批准号:6631991
- 负责人:
- 金额:$ 87.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-05-01 至 2005-03-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS AIDS /HIV diagnosis AIDS therapy antiAIDS agent chemoprevention clinical research clinical trials community health services cooperative study drug screening /evaluation human subject human therapy evaluation longitudinal human study opportunistic infections patient oriented research prognosis therapy compliance
项目摘要
DESCRIPTION (adapted from applicant's abstract): Louisiana, with a population
of just over 4 million people, ranked 9th highest in state AIDS case rates and
12th in AIDS cases reported in 1997. There are documented 16,112 cases of HIV
and of those, 10,320 have Acquired Immunodeficiency Syndrome (AIDS). As of
December 1997, more than 50 percent of the HIV/AIDS cases have been documented
in the New Orleans metropolitan statistical area and 18 percent of the cases
have been documented in the metro Baton Rouge statistical area. These
statistics rank New Orleans 11th highest among large cities in the nation.
Baton Rouge metro area ranks 19th in the nation. To address the local HIV
epidemic, academic and lay communities have successfully obtained funding
support for a variety of basic science and clinical research programs,
including the Louisiana Community AIDS Research Program (LaCARP).
LaCARP's goals in submitting this application are: (1) to continue
contributing to the CPCRA scientific agenda by active participation in CPCRA
scientific activities, including serving on national committees, concept and
protocol teams; (2) to continue to offer a variety of adult HIV clinical
research trials; (3) to continue to contribute high-quality data collected in
concordance with regulatory requirements; and (4) to continue serving as an
educational resource regarding HIV clinical trials and their results to local
medical and lay communities.
To achieve these goals, LaCARP specifically aims to: (1) administer this grant
from a centralized office and subcontract with successfully performing HIV
primary care sites in New Orleans and Baton Rouge; (2) maintain a scientific
advisory board to assist LaCARP in evaluating research concepts of high
priority; (3) maintain a strong community advisory board to ensure those
infected and affected by HIV have appropriate input into the national and
local design and implementation of research trials; and (4) enroll sufficient
numbers and types of study volunteers to answer scientifically important and
clinically relevant research questions. LaCARP has access to more than 4,000
patients among the 7 clinical sites and plans to enroll 180-225 patients a
year, with special emphases on strategy trials such as FIRST, PIP and the
observational studies of Metabolic Complications and Long-Term Follow-up.
描述(改编自申请人的摘要):路易斯安那州,人口
超过400万人,在州艾滋病发病率中排名第九,
在1997年报告的艾滋病病例中排名第12位。 记录在案的艾滋病毒感染病例为16,112例
其中10,320人患有艾滋病。 截至
到1997年12月,已有50%以上的艾滋病毒/艾滋病病例被记录在案
在新奥尔良大都市统计区,
都被记录在巴吞鲁日统计区。 这些
统计数据显示新奥尔良在全国大城市中排名第11。
巴吞鲁日地铁区在全国排名第19位。 为了解决当地的艾滋病问题,
流行病、学术界和非专业团体成功地获得了资金,
支持各种基础科学和临床研究项目,
路易斯安那州社区艾滋病研究计划(LaCARP)
LaCARP的 提交此申请的目的是: (1)继续
通过积极参与CPCRA为CPCRA的科学议程做出贡献
科学活动,包括在国家委员会任职,
方案团队;(2)继续提供各种成人艾滋病临床
(3)继续提供高质量的数据,
符合监管要求;及(4)继续担任
向当地提供有关艾滋病毒临床试验及其结果的教育资源
医疗和非专业社区。
为了实现这些目标,LaCARP的具体目标是:(1)管理这笔赠款
从一个中央办公室,并与成功执行艾滋病毒
新奥尔良和巴吞鲁日的初级保健中心;(2)保持科学的
咨询委员会,以协助LaCARP在评估研究概念的高
(3)保持一个强大的社区咨询委员会,以确保这些
艾滋病毒感染者和受艾滋病毒影响者的适当投入,
当地设计和实施研究试验;(4)招募足够的
研究志愿者的数量和类型,以回答科学上重要的问题,
临床相关研究问题。 LaCARP可以访问4000多个
7家临床研究中心中的患者,计划入组180-225例患者a
年,特别强调战略试验,如第一,PIP和
代谢并发症的观察性研究和长期随访。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID M MUSHATT其他文献
DAVID M MUSHATT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID M MUSHATT', 18)}}的其他基金
LOUISIANA COMMUNITY AIDS RESEARCH PROGRAM (CPCRA)
路易斯安那社区艾滋病研究计划 (CPRA)
- 批准号:
7208341 - 财政年份:2000
- 资助金额:
$ 87.89万 - 项目类别:
LOUISIANA COMMUNITY AIDS RESEARCH PROGRAM (CPCRA)
路易斯安那社区艾滋病研究计划 (CPRA)
- 批准号:
7032155 - 财政年份:2000
- 资助金额:
$ 87.89万 - 项目类别:
LOUISIANA COMMUNITY AIDS RESEARCH PROGRAM (CPCRA)
路易斯安那社区艾滋病研究计划 (CPRA)
- 批准号:
6510773 - 财政年份:2000
- 资助金额:
$ 87.89万 - 项目类别:
LOUISIANA COMMUNITY AIDS RESEARCH PROGRAM (CPCRA)
路易斯安那社区艾滋病研究计划 (CPRA)
- 批准号:
6746844 - 财政年份:2000
- 资助金额:
$ 87.89万 - 项目类别:
LOUISIANA COMMUNITY AIDS RESEARCH PROGRAM (CPCRA)
路易斯安那社区艾滋病研究计划 (CPRA)
- 批准号:
6021757 - 财政年份:2000
- 资助金额:
$ 87.89万 - 项目类别:
LOUISIANA COMMUNITY AIDS RESEARCH PROGRAM (CPCRA)
路易斯安那社区艾滋病研究计划 (CPRA)
- 批准号:
6373740 - 财政年份:2000
- 资助金额:
$ 87.89万 - 项目类别:
PHASE III SAFETY AND EFFICACY OF ABT-538 PLUS CURRENT THERAPY IN HIV PATIENTS
ABT-538 加上当前疗法在 HIV 患者中的 III 期安全性和有效性
- 批准号:
6253155 - 财政年份:1997
- 资助金额:
$ 87.89万 - 项目类别:
PLACEBO CONTROLLED STUDY OF SAFETY OF ADEFOVIR DIPIVOXIL IN HIV INFECTED PATIENTS
阿德福韦酯对 HIV 感染患者的安全性安慰剂对照研究
- 批准号:
6253197 - 财政年份:1997
- 资助金额:
$ 87.89万 - 项目类别: